Abstract
Interleukin-37 (IL-37) is a potent anti-inflammatory cytokine that plays a crucial protective role in cancer, autoimmune diseases, and inflammatory diseases through its unique dual intracellular and extracellular action pathways. This review highlights the significance of IL-37 in common respiratory diseases. Specifically, IL-37 can alleviate asthma by inhibiting Th2/Th17 immune responses, inhibiting the release of epithelial-derived alarmins (TSLP and IL-33), and attenuating airway remodeling. In pulmonary infections, IL-37 modulates host responses by mitigating virus-induced hyperinflammation and inhibiting viral replication, as observed in COVID-19 and influenza, while also regulating immunopathology in Mycobacterium tuberculosis and fungal infections. Moreover, in non-small cell lung cancer (NSCLC), IL-37 directly suppresses tumor proliferation and migration, and restrains tumor progression through immunomodulation and angiogenesis regulation. In pulmonary fibrosis, IL-37 reduces collagen deposition and promotes autophagy, thereby counteracting interstitial fibrosis. Collectively, these findings demonstrate that IL-37 serves as a crucial immunomodulator in respiratory diseases, and targeting IL-37 offers novel insights and strategic opportunities for clinical intervention.
Introduction
Respiratory diseases, ranging from chronic conditions like asthma and pulmonary fibrosis to acute infections like COVID-19 and influenza, are leading causes of global morbidity and mortality. A common thread across these diverse diseases is inflammatory damage and immune dysregulation, often manifesting as "cytokine storms" or chronic tissue remodeling. Current pharmacological treatments, such as corticosteroids, often suffer from limited efficacy, drug resistance, or severe side effects. Interleukin-37 (IL-37), a member of the IL-1 family, has emerged as a natural "brake" on the immune system, uniquely positioned to restore homeostasis without completely compromising host defense systems.
Molecular Mechanisms of IL-37 Action
Unlike conventional cytokines that function solely in the extracellular space, IL-37 operates via a unique bimodal signaling mechanism.
Bimodal Signaling
Extracellularly, IL-37 binds to a receptor complex consisting of IL-18Rα and IL-1R8 (also known as SIGIRR). This binding triggers a signaling cascade that broadly suppresses pro-inflammatory pathways, such as NF-κB and MAPK. Intracellularly, the precursor form of IL-37 is cleaved by caspase-1 into a mature form. This mature IL-37 binds to Smad3 and translocates into the nucleus, where it directly regulates the transcription of inflammatory genes.
Cellular Modulation
IL-37 actively shifts macrophage polarization from the pro-inflammatory M1 phenotype to the tissue-repairing, anti-inflammatory M2 phenotype. It also inhibits the maturation and function of dendritic cells (DCs), thereby dampening the activation of T-cell-mediated immune responses.
IL-37 in Chronic Airway Diseases
In asthma, IL-37 plays a pivotal role in suppressing the allergic inflammatory response. It inhibits the production of Th2 (IL-4, IL-5, IL-13) and Th17 (IL-17) cytokines, which are central to airway inflammation and hyperresponsiveness. Furthermore, IL-37 reduces the release of epithelial-derived alarmins like TSLP and IL-33, effectively "calming" the airway epithelium and reversing airway remodeling (thickening of the airway walls).
IL-37 in Pulmonary Infections and Malignancy
Viral and Bacterial Infections
IL-37's immune-dampening effects are highly beneficial in viral infections where hyperinflammation causes significant tissue damage. In COVID-19 patients, higher plasma IL-37 levels correlate with shorter hospital stays and faster viral clearance. However, this immunosuppression can be a "double-edged sword" in certain bacterial (e.g., Streptococcus pneumoniae) or fungal infections, potentially weakening the innate immune system's ability to clear pathogens.
Lung Cancer and Fibrosis
In Non-Small Cell Lung Cancer (NSCLC), IL-37 expression is typically downregulated. It directly inhibits tumor migration, suppresses tumor angiogenesis, and prevents tumors from evading the immune system via regulatory T cells (Tregs). In pulmonary fibrosis, IL-37 reduces collagen deposition and promotes cellular autophagy, counteracting the progression of interstitial fibrosis.
Discussion and Future Perspectives
IL-37 shows significant promise as a diagnostic and prognostic biomarker. For instance, the co-expression of IL-37 and IL-18BP serves as a highly discriminative marker for active pulmonary tuberculosis. However, several challenges remain for clinical translation, including the need for rigorous dose-response profiling to avoid paradoxical pro-inflammatory effects at high doses and the development of stable delivery mechanisms for lung-specific targeting.
In conclusion, IL-37 is a versatile immunomodulator whose unique mechanisms offer a sophisticated approach to managing complex respiratory diseases. Future large-scale clinical trials are essential to definitively validate its therapeutic utility.
Summary updated